



ORAL PRESENTATION

Open Access

Increased allergen-specific IgG4 levels are linked to suppressed IgE titers when analysed by ISAC but not by immunocap

Hans Jürgen Hoffmann^{1*}, Johannes Schmid¹, Peter Adler Würtzen², Ronald Dahl¹From 5th International Symposium on Molecular Allergology (ISMA 2013)
Vienna, Austria. 6-7 December 2013

Allergen specific immunotherapy (ASIT) is the only disease modifying treatment of allergic diseases. A key element in the protective effect is thought to be induction of a specific IgG4 response leading to a decrease in the IgE-mediated allergic symptoms. The effect of ASIT can be ascertained by provocation or skin prick testing. IgE measurement by ImmunoCAP is a sensitive standard procedure for allergy diagnosis and this has recently been supplemented by a single allergen array (ISAC), which employs significantly lower amounts of allergen and may have different assay dynamics. 24 subjects suffering from allergic rhinitis due to grass pollen allergy were stratified on basis of sensitivity in a basophil activation test, to receive standard subcutaneous immunotherapy (n=18) or to an open control group (n=6). Allergen specific IgE and IgG4 was measured at baseline and when reaching maintenance dose by using both the quantitative ImmunoCAP for Phl p1 and Phl p5 and the chip-based semi-quantitative ISAC method (Phl p 1, 2, 4, 5, 6, 7, 11 and 12). Data are presented as mean and 95% CI. ASIT treatment reduced self-reported symptoms from 10,7 to 5,5 (p=0,0001). ASIT increased allergen specific IgG4 levels, both by ISAC (from 0,3 to 5,0 ISAC specific units (ISU) (Δ 4,7 ISU; 2,7-6,7 ISU; p=0,0001) and ImmunoCAP (from 0,1 to 5,2 mg/l, Δ 5,1 mg/l; 2,3-7,9 mg/ml; p=0,0006). Specific IgE increased from 23,0 to 48,8 kU/l when measured by ImmunoCAP (Δ 25,8 kU/l; 4,4-47,2; p=0,01). Surprisingly, ISAC measurement of specific IgE decreased from 21,4 to 2,5 ISU (Δ 18,9 ISU; -10,0;-27,8; p=0,0002) during up dosing. No significant changes in IgG4 or IgE measurements were found in the control group during the treatment period. ImmunoCAP

measurements indicate that IgG4 and IgE increase during ASIT up dosing as previously reported. In contrast, when IgE in the same serum samples was measured by ISAC a decrease in IgE seems to be the result of successful ASIT. This may be the result of inhibition of IgE-binding in vitro in the ISAC assay, possibly reflecting functional IgE inhibition in vivo in the treated patients. ISAC measurements before and after ASIT may thus be useful in monitoring the clinical effect of allergen specific immunotherapy.

Authors' details

¹Aarhus University, Department of Clinical Medicine, Aarhus, Denmark.
²ALK-Abello, Experimental Immunology, Hørsholm, Denmark.

Published: 17 March 2014

doi:10.1186/2045-7022-4-S2-O20

Cite this article as: Hoffmann et al: Increased allergen-specific IgG4 levels are linked to suppressed IgE titers when analysed by ISAC but not by immunocap. *Clinical and Translational Allergy* 2014 **4**(Suppl 2):O20.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Aarhus University, Department of Clinical Medicine, Aarhus, Denmark
Full list of author information is available at the end of the article